Kurssprünge stehen jetzt bevor !!
Top-News
Centrex hat den Boden erreicht !!
Beiträge:
48
Zugriffe: 3.331 / Heute: 1
Zugriffe: 3.331 / Heute: 1
|
| 22 Beiträge ausgeblendet. |
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +73,81%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +64,99%
Amundi Russell 1000 Growth UCITS ETF - Acc
Perf. 12M: +38,69%
Amundi MSCI Wld Clim. Paris Align. PAB Umw. UCITS ETF DR C/D
Perf. 12M: +37,93%
WEITER !!!!!!!!!!
Feb 10, 2004 (financialwire.net via COMTEX) -- (FinancialWire) Centrex (OTCBB:
CNEX) traded up 32.84% to close at $0.089 Monday on volume of 11,446,690, or 12
times its average volume of $991,016, following an announcement that Micronics,
Inc. has advanced the development of an assay that contains Centrex's single
molecule nucleic acid detection technology for application in a
laboratory-on-a-card format.
Micronics reported to Centrex that it has achieved the initial milestone which
permits lysis and binding reactions in the lab card format.
The company said SMD technology, in combination with an easy-to-operate lab card
device and integrated reader, is expected to be responsive to the need for
rapid, user friendly and cost effective solutions for point-of-use analyses of a
variety of bacterial and viral organisms.
Centrex's SMD technology was exclusively licensed from Los Alamos National
Laboratories, and offers important advantages over existing DNA and RNA
detection methods as well as culture-based test methods. SMD technology
eliminates the need for amplification of the target DNA by recognizing the
unique DNA or RNA fingerprint of the target organism. This reduces the
possibility of false positive and negative test results - common concerns
frequently identified with other test procedures.
As a next step in the development process, Micronics is expected to integrate
the lysing/binding reactions together with SMD using a biological stimulant, the
spores of the bacteria Bacillus globigii. Bacillus globigii prepared in this
manner may be used safely to simulate Bacillus anthracis (anthrax) spores in the
DNA extraction and binding experiments.
Centrex was enrolled in Investrend Research's unique and pioneering professional
analyst program, which facilitates independent analysts to provide financial
coverage for shareholders and investors in companies that otherwise would have
little or no analyst following, but its coverage is presently suspended due to
the company's failure to provide access to the analyst as required by the issuer
standards of the Association for Investment Management and Research.
The Investrend Research program is the largest in the world and includes a
number of safeguards to reduce or eliminate conflict. These systems, including
media coverage and endorsements, may be accessed at
www.investrendresearch.com
Investrend Research is a member of the FIRST Research Consortium at
www.firstresearchconsortium.com, and participates in the organization's
standards development panel for independent research providers. The
"Standards for Independent Research Providers" may be viewed at
www.investrend.com/Admin/Topics/Articles/...871_1060440861.doc
The Dow Jones (NYSE: DJ) Newswires has stated that independent research has been
growing in credibility over the past 18 months, specifically citing Investrend
Research, and the New York Times (NYSE: NYT) has reported a survey by Charles
Schwab & Co. (NYSE: SCH) reveals an astonishing 78 percent of active
stockholders now "value research from independent firms over analysis by
Wall Street firms with financial ties to the companies they are rating." A
survey at Investopedia reveals that 74.7% of investors say that "legitimate
fee-based research is objective and useful," and 70.9% say that a company that
enrolls for "legitimate fee-based research is making a positive statement
about its investment potential."
Enrollment fees for Institutional coverage were $23,400, and the fees were paid
by the company. There is an open invoice for $13,700 remaining on account. There
are never any fees associated with FinancialWire, which independently covers a
wide range of corporate news, including but not limited to those that are or
have been enrolled in Investrend's platforms.
Complete information about any company enrolled in an Investrend shareholder
empowerment platform, including those of its affiliates and independent analysts
and webcasters, including disclosures and disclaimers, is available at the
company's InvestorPower page at
www.investrend.com/company/list.asp?sPathParam=yes , and on each report
and press release, and investors are advised to read those disclosures carefully
before trading in the equities of any enrolled company.
For up-to-the-minute news, features and links click on
www.financialwire.net
FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press
release service and receives no compensation for its news or opinions. Other
divisions of Investrend, however, provide shareholder empowerment platforms such
as forums, independent research and webcasting. For more information or to
receive the FirstAlert daily summary of news, commentary, research reports,
webcasts, events and conference calls, click on
www.investrend.com/contact.asp
The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: www.investrend.com/XmlFeeds?level=268
URL: www.financialwire.net
(C) 2004 financialwire.net, Inc. All rights reserved.
CNEX) traded up 32.84% to close at $0.089 Monday on volume of 11,446,690, or 12
times its average volume of $991,016, following an announcement that Micronics,
Inc. has advanced the development of an assay that contains Centrex's single
molecule nucleic acid detection technology for application in a
laboratory-on-a-card format.
Micronics reported to Centrex that it has achieved the initial milestone which
permits lysis and binding reactions in the lab card format.
The company said SMD technology, in combination with an easy-to-operate lab card
device and integrated reader, is expected to be responsive to the need for
rapid, user friendly and cost effective solutions for point-of-use analyses of a
variety of bacterial and viral organisms.
Centrex's SMD technology was exclusively licensed from Los Alamos National
Laboratories, and offers important advantages over existing DNA and RNA
detection methods as well as culture-based test methods. SMD technology
eliminates the need for amplification of the target DNA by recognizing the
unique DNA or RNA fingerprint of the target organism. This reduces the
possibility of false positive and negative test results - common concerns
frequently identified with other test procedures.
As a next step in the development process, Micronics is expected to integrate
the lysing/binding reactions together with SMD using a biological stimulant, the
spores of the bacteria Bacillus globigii. Bacillus globigii prepared in this
manner may be used safely to simulate Bacillus anthracis (anthrax) spores in the
DNA extraction and binding experiments.
Centrex was enrolled in Investrend Research's unique and pioneering professional
analyst program, which facilitates independent analysts to provide financial
coverage for shareholders and investors in companies that otherwise would have
little or no analyst following, but its coverage is presently suspended due to
the company's failure to provide access to the analyst as required by the issuer
standards of the Association for Investment Management and Research.
The Investrend Research program is the largest in the world and includes a
number of safeguards to reduce or eliminate conflict. These systems, including
media coverage and endorsements, may be accessed at
www.investrendresearch.com
Investrend Research is a member of the FIRST Research Consortium at
www.firstresearchconsortium.com, and participates in the organization's
standards development panel for independent research providers. The
"Standards for Independent Research Providers" may be viewed at
www.investrend.com/Admin/Topics/Articles/...871_1060440861.doc
The Dow Jones (NYSE: DJ) Newswires has stated that independent research has been
growing in credibility over the past 18 months, specifically citing Investrend
Research, and the New York Times (NYSE: NYT) has reported a survey by Charles
Schwab & Co. (NYSE: SCH) reveals an astonishing 78 percent of active
stockholders now "value research from independent firms over analysis by
Wall Street firms with financial ties to the companies they are rating." A
survey at Investopedia reveals that 74.7% of investors say that "legitimate
fee-based research is objective and useful," and 70.9% say that a company that
enrolls for "legitimate fee-based research is making a positive statement
about its investment potential."
Enrollment fees for Institutional coverage were $23,400, and the fees were paid
by the company. There is an open invoice for $13,700 remaining on account. There
are never any fees associated with FinancialWire, which independently covers a
wide range of corporate news, including but not limited to those that are or
have been enrolled in Investrend's platforms.
Complete information about any company enrolled in an Investrend shareholder
empowerment platform, including those of its affiliates and independent analysts
and webcasters, including disclosures and disclaimers, is available at the
company's InvestorPower page at
www.investrend.com/company/list.asp?sPathParam=yes , and on each report
and press release, and investors are advised to read those disclosures carefully
before trading in the equities of any enrolled company.
For up-to-the-minute news, features and links click on
www.financialwire.net
FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press
release service and receives no compensation for its news or opinions. Other
divisions of Investrend, however, provide shareholder empowerment platforms such
as forums, independent research and webcasting. For more information or to
receive the FirstAlert daily summary of news, commentary, research reports,
webcasts, events and conference calls, click on
www.investrend.com/contact.asp
The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: www.investrend.com/XmlFeeds?level=268
URL: www.financialwire.net
(C) 2004 financialwire.net, Inc. All rights reserved.
eigentlich nur eine Bestätigung der gestrigen news, oder ?
überbewertet gegenüben dem Referenzkurs 0,089 zu 1,2780 $ macht 0,07 EUR und nicht 0,076 EUR. In der Euphorie steckt quasi schon der Kursanstieg heute mit drin, wenn die Amis nicht im Plus öffnen, dann schlägt die Schnalle in die Gegenrichtung.
Der sk vom Freitag war 0,067$ und wir sind hoch auf 0,062€ bis zur Ami Eröffnung.
Die haben dann übernommen und sind bis auf 0,089$ geflitzt.
Nachbörslich sogar ein trade zu 0,09$
Im Moment geht nix unter 0,076€.Der Umsatz ist schon nicht schlecht.Wenn der Ami allerdings wieder mitzieht,dann sehen wir schnell die 0,10$ heute und dann bekommt hier keiner mehr eine unter 0,08€.
Dementsprechend wären die Kurse unter 0,08€ noch in Ordnung.
Das ist nur meine persönliche Meinung.
Grüße joker
Die haben dann übernommen und sind bis auf 0,089$ geflitzt.
Nachbörslich sogar ein trade zu 0,09$
Im Moment geht nix unter 0,076€.Der Umsatz ist schon nicht schlecht.Wenn der Ami allerdings wieder mitzieht,dann sehen wir schnell die 0,10$ heute und dann bekommt hier keiner mehr eine unter 0,08€.
Dementsprechend wären die Kurse unter 0,08€ noch in Ordnung.
Das ist nur meine persönliche Meinung.
Grüße joker
Ich denke die Chancen stehen gut, da der Kurs am TAgeshöchtstand stehn geblieben ist und das mit einem grossen Spurt am Ende, der durch den Börsenschluss leider gestoppt wurde!
Bin aber etwasunsicher bei dem Kurs reinzugehen. Die Nachrichten waren doch gestern zur US Boersenzeit schon bekannt denke ich!? Ob s wirklich noch raufgeht oder erst konsolidiert?
2,7 Mio.gehandelt.
Die meisten sind aus dem ask gekauft worden.
Mein Tipp das geht heute weiter.
0,11$
Mich aber nicht schlachten wenn es nur bis 0,109 geht *g*
Gruß joker
Die meisten sind aus dem ask gekauft worden.
Mein Tipp das geht heute weiter.
0,11$
Mich aber nicht schlachten wenn es nur bis 0,109 geht *g*
Gruß joker
konsolidieren, aber die kleine Rally, die durch den Börsenschluss gestoppt wurde stimmt mich positiv! Die News sind ja erst seit gestern raus und denke dass die noch andere Interessierte erreichen wird...
Centrex wird gleich richtig durchstarten!
Alles unter 10 Cent is spottbillig!!!!
mfg:)
Alles unter 10 Cent is spottbillig!!!!
mfg:)
dass ein weiterem Anstieg nichts im Wege steht ?
Meilensteinzahlung! Das bedeutet, dass sie finanziell wieder etwas besser da stehen, aber hauptsächlich, dass sie auch Fortschritte machen!!
meinen rt Zugriff:(((
Wie ist denn das Volumen aktuell??
Danke joker
Wie ist denn das Volumen aktuell??
Danke joker
D.h. keiner schmeißt.Es wird alles wacker gehalten !!
Oder sieht das jemand anders ??
Oder sieht das jemand anders ??
nein sehe ich auch so - hätte eigentlich noch auf größere konsolidierung warten wollen aber bin jetzt um 0,68 rein weil ich denke billiger bekomm ich sie morgen auch nicht *g*
Latest Quote
Last: 0.087
High: 0.087
Low: 0.086
Open: 0.087
Change: +0.000
Volume: 173,000
Bid: 0.085
Ask: 0.100
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.175
52 Wk Low: 0.032
%Change: 0.0%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Market Data Powered By ComStock
02/11/04 - 9:48 a.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
09:46:32 0.087 50000 OTCBB
09:46:20 0.087 18000 OTCBB
09:33:29 0.087 10000 OTCBB
09:33:28 0.086 35000 OTCBB at Bid
09:33:27 0.087 20000 OTCBB
09:22:59 0.087 20000 OTCBB at Bid
Last: 0.087
High: 0.087
Low: 0.086
Open: 0.087
Change: +0.000
Volume: 173,000
Bid: 0.085
Ask: 0.100
Bid/Ask Size: 5,000 / 5,000
52 Wk High: 0.175
52 Wk Low: 0.032
%Change: 0.0%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Market Data Powered By ComStock
02/11/04 - 9:48 a.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
09:46:32 0.087 50000 OTCBB
09:46:20 0.087 18000 OTCBB
09:33:29 0.087 10000 OTCBB
09:33:28 0.086 35000 OTCBB at Bid
09:33:27 0.087 20000 OTCBB
09:22:59 0.087 20000 OTCBB at Bid
Latest Quote
Last: 0.081
High: 0.087
Low: 0.081
Open: 0.087
Change: -0.006
Volume: 903,000
Bid: 0.075
Ask: 0.081
Bid/Ask Size: 5,000 / 40,000
52 Wk High: 0.175
52 Wk Low: 0.032
%Change: -6.9%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Market Data Powered By ComStock
02/11/04 - 10:30 a.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
10:27:56 0.081 10000 OTCBB
10:27:36 0.081 5000 OTCBB
10:27:10 0.081 10000 OTCBB
10:26:34 0.082 60000 OTCBB
10:26:29 0.081 100000 OTCBB
Last: 0.081
High: 0.087
Low: 0.081
Open: 0.087
Change: -0.006
Volume: 903,000
Bid: 0.075
Ask: 0.081
Bid/Ask Size: 5,000 / 40,000
52 Wk High: 0.175
52 Wk Low: 0.032
%Change: -6.9%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Market Data Powered By ComStock
02/11/04 - 10:30 a.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
10:27:56 0.081 10000 OTCBB
10:27:36 0.081 5000 OTCBB
10:27:10 0.081 10000 OTCBB
10:26:34 0.082 60000 OTCBB
10:26:29 0.081 100000 OTCBB
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem CANNON EXPL INC Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
3 | 96 | Kriminelle Kursmanipulationen von Börsenbriefen, | geldschneider | geldschneider | 21.08.05 13:10 | |
| 24 | Centrex WKN:541434 | soros | Zwergnase | 25.07.05 16:53 | ||
| 594 | Centrex strong buy 0,05 noch! Bio!12% | soros | Meiko | 22.03.05 10:57 | ||
| 53 | Centrex, schaut aus wie ZOCK, ist aber keiner !! | SchwarzerHengst | soros | 25.04.04 19:56 | ||
| 26 | OTC Turnarounds Charts | soros | lancerevo7 | 17.04.04 16:05 |
